Aclaris Therapeutics (ACRS) Non-Current Assets (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Non-Current Assets of $88.5 million for Q1 2026, down 0.91% year-over-year from $89.3 million in Q1 2025, and up 37.96% quarter-over-quarter from $64.1 million in Q4 2025.
Aclaris Therapeutics (ACRS) Non-Current Assets (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Non-Current Assets history runs 13 years deep, the most recent figure standing at $88.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 0.91% year-over-year to $88.5 million; the TTM figure through Mar 2026 stood at $312.5 million (up 12.75% YoY), while the FY2025 annual figure was $64.1 million, down 32.03% from the prior year.
- Non-Current Assets for Q1 2026 stood at $88.5 million, up from $64.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $102.7 million in Q2 2023, with the low at $11.1 million in Q3 2022.
- The 5-year median for Non-Current Assets is $64.1 million (2025), against an average of $60.5 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets slumped 80.84% in 2022, then jumped 761.61% in 2023.
- Aclaris Therapeutics' Non-Current Assets stood at $23.0 million in 2022, then soared by 197.44% to $68.5 million in 2023, then surged by 37.68% to $94.4 million in 2024, then sank by 32.03% to $64.1 million in 2025, then soared by 37.96% to $88.5 million in 2026.
- Business Quant data shows ACRS's Non-Current Assets at $88.5 million in Q1 2026, $64.1 million in Q4 2025, and $74.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 81.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.93 Mn |
| Mar 31, 2026 | 88.49 Mn |
| Dec 31, 2025 | 64.14 Mn |
| Sep 30, 2025 | 74.94 Mn |
| Jun 30, 2025 | 84.95 Mn |
| Mar 31, 2025 | 89.30 Mn |
| Dec 31, 2024 | 94.38 Mn |
| Sep 30, 2024 | 50.06 Mn |
| Jun 30, 2024 | 43.44 Mn |
| Mar 31, 2024 | 38.73 Mn |
| Dec 31, 2023 | 68.55 Mn |
| Sep 30, 2023 | 95.29 Mn |
| Jun 30, 2023 | 102.71 Mn |
| Mar 31, 2023 | 45.34 Mn |
| Dec 31, 2022 | 23.05 Mn |
| Sep 30, 2022 | 11.06 Mn |
| Jun 30, 2022 | 18.62 Mn |
| Mar 31, 2022 | 35.65 Mn |
| Dec 31, 2021 | 46.18 Mn |
| Sep 30, 2021 | 57.71 Mn |